A long-sought FTD diagnosis can give families a sense of closure: Finally, a reason for our loved one’s decline. But new questions quickly emerge. What is FTD, anyway? What’s going to happen? How long will this journey last? And what if FTD runs in our family?
Researchers have identified more than a dozen genes in which variants cause FTD, and these variants can be passed down from generation to generation, a biological fact that brings profound worry and fear to families already reeling from their loved one’s FTD diagnosis. In recent years, the AFTD community has expressed a desire to learn more about genetic FTD, particularly because many clinical trials are exclusively recruiting participants who know they have specific genetic causes for FTD (rather than those with so-called sporadic FTD). Families without a known history of FTD have asked if research into the disease’s genetic causes may have implications for the broader FTD community.
On May 1, AFTD gave our community the chance to have their questions answered at our first-ever Genetic FTD Symposium, which kicked off the 2025 AFTD Education Conference. (See page 6 for a full Conference recap.) Clinical and research experts on FTD genetics joined members of our community with genetic FTD experience to present sessions on the science of genetic FTD, clinical trials, and how to become a genetic FTD advocate.
AFTD Manager of Genetic Initiatives Kim Jenny, MS, led off the Symposium with an overview of the basics – how FTD can be passed down, why genetic testing is so important, and what you can do before learning whether you carry an FTD-causing genetic variant. A licensed certified genetic counselor herself, Jenny emphasized the importance of counseling, which can help you decide if testing is right for your family and, later, explain your results.
The Symposium encouraged audience participation. During one session, genetic counselor Brook Croke, MS, of Synapticure, a telehealth company that focuses on neurodegenerative disease, joined Jenny on stage to answer audience questions. In another session, AFTD Senior Director of Scientific Initiatives Penny Dacks, PhD, moderated a townhall discussion that allowed members of our community to ask scientists about research on genetic FTD.
Amanda Gleixner, PhD, AFTD’s Research Projects Manager, led a session describing the current clinical trial landscape for FTD. She explained that many of the most mature trials are currently recruiting people with a confirmed genetic cause because they can be more confident that their FTD has been correctly diagnosed, and have a better understanding of how to intervene in the disease process.
Although people with apparently sporadic FTD do not always meet inclusion criteria for current clinical trials, they can still benefit from them. “Clinical trials from one form, or type, of FTD will drive the progress for drug development in all forms of FTD,” Dr. Gleixner said. After her presentation, representatives from six companies with active trials in genetic FTD – Alector, Denali, Passage Bio, Prevail, Vesper Bio, and AviadoBio – each explained their approach to treating FTD. (To learn about FTD studies that are actively recruiting, visit the FTD Disorders Registry at FTDregistry.org and click “Find a Study.”)
The Symposium closed with a session on genetic FTD advocacy. Three AFTD volunteers – Linde Jacobs, RN; Wanda Smith; and AFTD Ambassador Joanne Linerud – spoke about the ways people can advocate for genetic FTD families: participating in research, volunteering with AFTD, and bringing awareness of genetic FTD to policymakers.
“Advocacy brings people together,” said AFTD Director of Advocacy and Volunteer Engagement Meghan Buzby, MBA, who led the session. “It brings everyone here in this room together to take collective action. It builds momentum for social and healthcare changes, creating a stronger – and, most importantly, unified – voice for everyone affected or impacted by FTD.”
A playlist of recordings from the Symposium is available at youtube.com/theAFTDorg. Because the Symposium included questions from attendees, the event was not livestreamed. Publicly divulging one’s genetic FTD status is a deeply personal choice, and AFTD did not want to inadvertently broadcast any sensitive information from those asking questions.
AFTD will continue to listen and respond to our community’s needs as they emerge. Visit theaftd.org/what-is-ftd/genetics-overview for more information on genetic FTD.
FDA Approves Blood Test for Alzheimer’s Disease
In May, the U.S. Food and Drug Administration approved a method of using a standard blood draw to detect the presence of Alzheimer’s disease in the body with more than 90 percent accuracy. Previously, Alzheimer’s pathology could only be detected with a PET scan or a lumbar puncture. Experts say that the newly approved Alzheimer’s blood test may accelerate diagnoses for people with FTD.
Dr. Chiadi Onyike Becomes AFTD Medical Advisory Council Chair
AFTD is pleased to announce that Chiadi Onyike, MD, is the new chair of our Medical Advisory Council (MAC). A specialist in neuropsychiatry, Dr. Onyike is the director of both the Frontotemporal Dementias Program and the Young-Onset Dementias Program at Johns Hopkins University. Carmela Tartaglia, MD, of the University of Toronto, is the new MAC chair-elect.
Leonard Lauder, 1933-2025
AFTD remembers Leonard A. Lauder, who died in June at age 92, as a cosmetics-industry legend who significantly advanced the search for dementia treatments by co-founding the Alzheimer’s Drug Discovery Foundation (ADDF). AFTD and ADDF have partnered to create FTD research funding opportunities such as Accelerating Drug Discovery for FTD and the Treat FTD Fund. For his generosity, AFTD presented Mr. Lauder with the Susan Newhouse & Si Newhouse Award of Hope in 2018.
Recognizing that FTD care partners needed a place to connect and share information, Helen-Ann Comstock, a former caregiver and founder of AFTD, established the first FTD-focused support group in the late 1990s.
What started as a handful of people meeting in “nothing more than a closet in an office building” is now a nationwide network with in-person and virtual meeting options with:
Joe Pang
“I started co-facilitating the group I had joined as a care partner for my wife, Jackie, when the woman who had been running it could no longer do so. The group helped me get through what I felt was a nightmare, so after Jackie passed in 2020, I knew I had to continue as a facilitator for this group. It’s so important for people to have an outlet to ask questions or vent in an easy environment. My role now is to show people that life will continue, and it can be good if you let it be good.”
– Joe Pang, co-facilitator for a support group in New Jersey since 2017
Tanisha Gupta
“I felt completely lost when my mom was diagnosed with bvFTD. I was living far from my family and had trouble turning to friends for support. I soon realized that we needed a group bringing together similarly situated young adult children of individuals with FTD. I cannot imagine going through the FTD experience without our group.”
– Tanisha Gupta, facilitator for the National Young Adult Caregivers support group since 2021
Tammy Schmitz
“I love tending to the emotional and practical needs of caregivers in our group. I am inspired by the way they support each other through shared experiences, listening and offering insights and resources to support each other. When you support AFTD, you’re helping all those impacted by FTD: people with the disease, caregivers, families, friends, and the larger community.”
– Tammy Schmitz, facilitator for a virtual support group for people in the Twin Cities, Minnesota area since 2022
AFTD’s support group network is one of the many programs we offer to help people affected by FTD. With a gift today, you will join Joe, Tanisha, Tammy, and a community empowered to ensure these resources are accessible to those who need them while furthering research essential for timely and accurate diagnosis and therapeutic development.
Together, we can improve the journey for the next family.
Together, we are paving the path forward to #endFTD.
Click here to give today.
You can ask Len Marquez why he joined the AFTD Board, but a better question might be: How could he not?
Marquez already had several connections to AFTD before he joined the Board earlier this year. His cousin Joseph Marquez is a Board member; another, Shoshana Derrow Krilow, is a longtime professional associate. He went to high school with the sister of yet another Board member, David Pfeifer, with whom he’d recently reconnected. Finally, he works closely with the husband of Sandy Cannon, an AFTD Ambassador.
“Somebody wants me to do something here,” he concluded. His deepest connection to AFTD is, unfortunately, his family history. He’s lost his father, his paternal grandmother, and three of his father’s siblings. Several family members are involved in genetic testing through the University of California, San Francisco.
That history has given Marquez a sweeping view of the evolution of FTD awareness. His father passed away in 2003, when FTD was still commonly known as Pick’s disease. At the time, Marquez didn’t really know how to describe what his father was facing. “I used to tell people it was a kind of early-onset Alzheimer’s disease,” he said. “My father was a general surgeon, and I would say that he still remembered how to take out your gallbladder; he just couldn’t remember when he was scheduled to do it.”
Marquez is senior director of government relations and legislative advocacy at the Association of American Medical Colleges. There, he serves as the primary contact for members of Congress and their staff on issues impacting teaching health systems and hospitals, physicians, and patient care. Given AFTD’s strategic focus on legislative, policy, and regulatory advocacy, Marquez’s 30-plus years in government relations position him to make important contributions toward furthering our mission.
His goal on the Board is for AFTD to become better known among policymakers. “When policymakers on Capitol Hill are discussing any issue related to dementia or any neurodegenerative diseases, they should be thinking, ‘Where is AFTD on this? We need to make sure we get their insights,’” he said.
“What I can bring is a level of understanding that I hope can help shape and guide engagement, and really make us effective in advocating for what’s needed to maintain the progress underway towards effective treatments and a cure for FTD,” Marquez continued.
Marquez says that his wife and three daughters provided the motivation to join the AFTD Board to help pave the path forward to a future free of FTD. Serving on the AFTD Board “gives me an opportunity to help my kids, or anybody’s kids, maintain hope for the future.”
AFTD’s ninth Hope Rising Benefit, held April 3 at the Ziegfeld Ballroom in New York City, raised $1.9 million to support AFTD’s mission and pave the path forward to greater awareness, effective care, and research into urgently needed treatments for FTD.
Emma Heming Willis and Bruce Willis were to be honored with the Susan Newhouse & Si Newhouse Award of Hope. They could not make it in person due to the Los Angeles wildfires, but Mrs. Willis addressed the 400-plus guests in a video message, and will be in attendance at Hope Rising 2026 to accept the award on her and Bruce’s behalf.
The event’s Keynote Speech was delivered by Spencer Cline, an AFTD Ambassador whose father, Lawrence, had FTD and died in 2012. Last summer, Spencer honored his late father and raised funds for AFTD’s mission by biking across the entire United States, from Oregon to South Carolina.
In his speech Spencer recounted his two-month ride, including the broken collarbone he suffered in Georgia, with just about 300 miles to go. Since the injury prevented Spencer from biking the last stretch himself, the AFTD community made up the remaining miles by riding in their own communities on his behalf.
“While it was not the finish I ever imagined, it was almost more beautiful, and it sums up what AFTD is all about,” Spencer said at Hope Rising. “Having a loved one with FTD is impossible to get through alone. It takes a community of support rallying around you, lifting you up when you can’t keep going.”
Spencer was named ABC World News Tonight’s “Person of the Week” the day after the Benefit, with anchor David Muir introducing a segment devoted to his family’s FTD journey.
Journalist Paula Zahn reprised her annual role as Hope Rising’s master of ceremonies, while Academy Award–winning actress Ariana DeBose provided the evening’s musical entertainment.
As in previous years, AFTD Board member Donald Newhouse served as Benefit chair, along with co-chairs Anna Wintour (editor-in-chief, Vogue) and David Zaslav (CEO and president, Warner Bros. Discovery). AFTD Board member Kathy Newhouse Mele and Joan Berlin served as vice chairs.
The Susan Newhouse & Si Newhouse Award of Hope is named for Mr. Newhouse’s late wife and brother, both of whom had FTD.
The 10th annual Hope Rising will take place next year on March 12 in New York City.
More than 450 people came to Colorado for the 2025 AFTD Education Conference on May 1-2, with hundreds more attending virtually, making it AFTD’s most successful annual conference yet.
The two-day event kicked off with AFTD’s first-ever Genetic FTD Symposium, on May 1. Available exclusively for those who came to Broomfield, Colo., to attend the Conference in person, the half-day symposium addressed genetic FTD from all angles. (See cover story for details.)
Additional in-person events on May 1 included a social event for persons diagnosed and their care partners, as well as the FTD in the Arts exhibit, featuring artwork and poems produced by people on the FTD journey. Attendees could also join “reTHINK w/ Dementia Live,” an interactive workshop that simulates the sensory changes and cognitive difficulties caused by dementia to help engender greater empathy among those who have not been diagnosed.
The full Education Conference took place on May 2. Katie Brandt, MM, delivered the Keynote Address, in which she described her love story with her late husband, Mike, diagnosed with FTD when he was just 29. Mike learned he had FTD during a single three-week span in which Brandt’s mother died of a heart attack and her father was diagnosed with Alzheimer’s. Today, Brandt is the director of caregiver support services and public relations in Massachusetts General Hospital’s Frontotemporal Disorders Unit.
Members of AFTD’s Persons with FTD Advisory Council challenged preconceptions about FTD in a session entitled “Living Well with an FTD Diagnosis.” They highlighted the various challenges that FTD imposes each day, and shared methods and resources they use to overcome them as best they can.
The Education Conference ended with a rousing call to action from FTD advocate Emma Heming Willis and AFTD Director of Advocacy and Volunteer Engagement Meghan Buzby, MBA. Mrs. Willis told the 1,000-plus watching online and in person that, despite her initial reluctance, she has found deep meaning by throwing herself into FTD activism on behalf of all those diagnosed – including her husband, the actor Bruce Willis.
Other sessions focused on FTD’s motor symptoms, its symptomatic and pathological commonalities with ALS, and the federally run dementia-care initiative known as GUIDE (Guiding an Improved Dementia Experience).
For the second straight year, AFTD Ambassador Diana Gonzalez-Morett and dementia advocate Aisha Adkins, MPA, CNP, led a special Story Circles session during the Education Conference. Participants gathered in an intimate setting to share their emotional responses to having FTD in their lives.
In 2005, AFTD founder Helen-Ann Comstock and a group of medical advisors awarded $35,000 to Eileen Bigio, MD, a clinical researcher at Northwestern University, to identify abnormal proteins present in FTD with motor neuron features, like ALS. This first-ever AFTD research grant was given out while the organization was in just its third year – before before it even had paid staff.
Due to the success of the initial grant to Dr. Bigio, AFTD developed the Pilot Grant program, which offers seed money to help researchers generate data and secure more funding. Susan L-J Dickinson, MSGC, joined AFTD as executive director in 2008 (she is now CEO) and has continued to grow the vision of the Pilot Grant program. In the last two decades, the program has funded $2.8 million in innovative FTD research.
The impact of AFTD Pilot Grants is exemplified by Emily Rogalski, PhD, a clinical neuroscientist who in 2013 received funding to conduct a clinical trial called Communication Bridge. Communication Bridge is a telehealth-based speech-language intervention for people with primary progressive aphasia (PPA). A $60,000 AFTD Pilot Grant helped Dr. Rogalski show the positive impact of this intervention, allowing her to secure federal funding from the National Institute on Aging to conduct a phase 2 trial. Communication Bridge has now expanded into a phase 3 clinical interventional trial and continues to benefit people with PPA.
Over time, the Pilot Grant program split into two different grants: the Pathways for Hope Pilot Grant, which remains focused on biomedical research, and the Well-Being in FTD Pilot Grant, conceived by AFTD leadership to improve the quality of life for people living with FTD and their families. For example, Eline Bunnik, PhD, received a 2023 Well-Being in FTD Pilot Grant to study the ethical considerations and potential ramifications involved in disclosing the genetic status of people at risk of FTD.
Today, AFTD remains fully committed to continuing our investment in exceptional researchers working towards solutions for families affected by FTD. The focus of the investments will continue to evolve as the field progresses further towards the effective treatments so urgently needed by families. From the record number of applications AFTD received during the 2025 Pilot Grant cycle, three excellent recipients have been selected (see page 11).
We are deeply grateful to the many donors who have enabled us to maintain and expand this unique funding program over the past 20 years. Together, we will continue to support promising investigators with innovative ideas to achieve real progress for FTD research.
In recent months, AFTD awarded grants to scientists working on the leading edge of FTD research.
Pathways for Hope Pilot Grants target early-career researchers to seed funding for novel research. Cyril Pottier, PhD, from Washington University in St. Louis, will use this award to study genetic factors that may be protective in individuals with familial FTD, with the goal of identifying innovative treatment options.
Indira García Cordero, PhD, a research affiliate at San Andres University in Argentina, will use her award to study factors that influence white matter changes in the brains of people with behavioral variant FTD and how these may vary between individuals living in Latin America versus North America.
The Well-Being in FTD Pilot Grant was conceived by AFTD leadership to improve the quality of life for people living with FTD and their families. Stephanie Grasso, PhD, CCC-SLP, was awarded this grant to evaluate a bilingual support program helping Latino and Hispanic caregivers understand dementia, improve communication, manage stress, and prepare for the future.
Since 2007, AFTD and the Alzheimer’s Drug Discovery Foundation (ADDF) have partnered to support preclinical research on promising new FTD drugs through the Accelerating Drug Discovery for FTD Grant. This year’s first announced grant recipient is Thomas Kukar, PhD, at Emory University, who will conduct research into the development of a granulin biologic to treat progranulin-deficient FTD.
The Clinical Research Training Scholarship in FTD is made possible by the Holloway Family Fund, in collaboration with the American Academy of Neurology and the American Brain Foundation. Janani Parameswaran, PhD, has received a 2025 scholarship to further investigate variance in the C9orf72 gene, a known genetic risk factor for developing FTD and ALS.
The Holloway Postdoctoral Fellowship, funded solely by the Holloway Family Fund, provides funding for the next generation of FTD researchers. The 2025 fellowship recipients are Takumi Nakamura, MD, PhD, and Chang Liu, PhD.
Dr. Nakamura seeks to find when and which tau protein species change in the spinal fluid during disease progression, with the goal of enabling earlier detection of FTD. Dr. Liu will investigate how a unique kind of chemical modification to RNA can affect specific brain functions, with the goal of revealing underlying disease mechanisms and new potential treatments.
AFTD honored its volunteers at a special reception in Denver, Colo., held on May 1, the night before the AFTD 2025 Education Conference. We recognized 613 dedicated volunteers with thank-you gifts and a week of powerful social media spotlights. Thank you to all our amazing volunteers!
More than 130 volunteers and guests came together to celebrate the power of community, connection, and impact. AFTD expressed its gratitude with a shared meal, a moving video tribute, and custom water bottle holders—a heartfelt toast to ongoing advocacy and awareness. Visit theaftd.org/get-involved/volunteers-network to watch the video tribute.
AFTD Ambassadors offered visual proof that support for FTD families is growing nationwide, with a U.S. map showing where volunteers, support groups, and attendees came from.
At the May 3 Ambassador Summit, 28 AFTD Ambassadors from 24 states gathered to align with AFTD’s new three-year strategic plan—and fuel it with their insights and enthusiasm.
For the first time, AFTD’s Board, staff, and Ambassadors shared a regionally grouped breakfast, creating space for connection, collaboration, and fresh ideas for outreach.
The Ambassador Summit ended with a joyful Tex-Mex dinner and a chocolate piñata bursting with fruit and churros—a sweet end to a day full of purpose and passion!
AFTD staffers and advocates traveled to Albany, N.Y., on June 10 to support and thank legislators there for their efforts to establish the first state-level FTD registry in the country.
Earlier this year, State Sen. Michelle Hinchey reintroduced a bill that would create a new registry in New York, tasked with collecting data on the rate of clinical FTD diagnoses throughout the state. It passed the state Senate on May 28, and, with the help of Assemblywoman Amy Paulin, cleared the Assembly on June 6. The final step is the desk of Gov. Kathy Hochul for her signature.
“My bill to create the first state-level FTD Diagnosis Registry in the country will bring us closer to a world without FTD and produce a legislative model that can be replicated across all 50 states,” Sen. Hinchey said earlier this year.
Although FTD affects many Americans, the lack of nationwide awareness often leads to misdiagnoses as a psychiatric condition or a different neurodegenerative condition like Alzheimer’s disease. The focused data collection of state registries will help raise awareness of the scope of FTD among medical professionals and the public.
AFTD staff members Lauren Pelaia and Matt Sharp, from AFTD’s advocacy team, went to Albany to show their support. They were accompanied by several FTD advocates: Dorothy Pearman, who is living with an FTD diagnosis and was accompanied by family members Audriana Pearman and Robert Pearman; AFTD Ambassador Jackie Shapiro; and Annika Roll of Cure MAPT FTD, an advocacy group that works on behalf of people living with an FTD-causing variant in the MAPT gene.
In addition to acknowledging the lawmakers’ work, the AFTD delegation heard Sen. Hinchey deliver a heartfelt speech in which she introduced a resolution that designates September 21-27 Frontotemporal Degeneration Awareness Week in the State of New York, for the third consecutive year. The resolution passed the Senate.
Sen. Hinchey’s passionate advocacy stems from personal experience. Her father, former U.S. Congressman Maurice Hinchey, had primary progressive aphasia and died in 2017.
Sen. Hinchey previously introduced a bill that would have established a statewide FTD registry last year. That bill passed the Senate but was not voted on by the Assembly before the legislative session expired.
AFTD is deeply grateful to Sen. Hinchey and Assemblywoman Paulin for their leadership and their commitment to this critical issue.
How State FTD Registries Differ from the FTD Disorders Registry
Despite sharing the word “registry,” the proposed New York FTD registry differs significantly from the existing FTD Disorders Registry. The former would require clinicians to report all new FTD diagnoses—an important first step to establishing FTD’s actual prevalence in the state. The FTD Disorders Registry, meanwhile, is global in scope, and relies on voluntary participation from persons diagnosed and their loved ones, thus ensuring their lived experiences are incorporated into FTD research.
Join the FTD Disorders Registry by visiting FTDregistry.org.
Independent Events
The below events raised $1,000+ for our mission since the Spring 2025 issue of AFTD Insights:
Scott Campbell, the owner of My Lakeshore Subaru in Michigan, selected AFTD as the Hometown Charity this past winter for Subaru’s annual Share the Love event. AFTD Ambassador Dawn Ducca accepted the check on behalf of AFTD at My Lakeshore Subaru’s grand opening in April, where an incredible $24,650 was donated to AFTD. Scott and his wife Heidi chose AFTD because of their connection to the Sidoris family, who will be hosting their 20th annual GFS Memorial Golf Outing this August 2 just outside Cleveland, Ohio—AFTD’s longest running volunteer-led fundraiser, and clear inspiration for Scott and Heidi to want to make a similar impact on our mission.
Molly Quinn ran the 20th annual Holy Half Marathon throughout the University of Notre Dame’s campus on March 16 in memory of her grandfather, Ed McAndrews, who had FTD and died in 2005. She was joined by family members Claire, Kelly, Brendan, and her mother, Colleen, an AFTD Board Alumna (2005–2012). Together, they crushed 65.5 miles and raised $7,299 to end FTD.
Thomas Murdoch participated in the 2025 United Airlines NYC Half Marathon on March 16 in honor of his mother, who is living with FTD. He used the event to spread vital FTD awareness and raise funds to benefit AFTD’s mission – $5,844 worth.
AFTD Board member Valerie Snow held a virtual fundraiser in memory of her father, Jim. She shared her touching story and information about FTD to spread awareness, and raised a total of $4,754 for AFTD’s mission!
Guy Margolin, who is living with FTD, and Lauren Pelaia, AFTD’s Advocacy Coordinator, hosted a Dueling Pianos Night on April 1 at Leisure Village West in New Jersey. The event, in collaboration with the Pickleball Club and the Flying Ivories, featured a live music competition and raffles, and raised $4,281 in vital funds for FTD awareness.
Emily Addleson and her husband Eddy ran the Maine Coast Marathon on May 3 to honor her father, James Chadwick, who is living with FTD. A passionate runner, Emily turned her miles into impact as she raised $2,011 and spread untold awareness for FTD.
Amar Sharma hosted the third annual Ball to End Dementia Tournament in March at his high school in Houston. This event had it all: basketball, prizes, food, raffles, half-time games, and more! Students formed teams to compete against faculty members for a grand prize. The event raised $1,162 to support AFTD’s mission, bringing their grand total to $3,075 donated the past three years.
Peter Agugliaro got married in March and in lieu of wedding gifts, the couple asked friends and family to make a donation in memory of his father, John. The newlyweds collected a total of $1,155 for AFTD’s mission.
Sam Leverson is an instructor at CycleBar in Minneapolis and used his passion for cycling to host a fundraiser for AFTD in honor of his father, Sven, who is living with FTD. As a special Father’s Day ride, on June 15, he cycled his way to untold awareness and raised $1,444 to end FTD.
AFTD’s Events Department would like to extend a THANK YOU to the additional fundraising volunteers who hosted an event this past quarter: Libba Adams, Michele Howerter, Cody Zickler, Alan Persaud, Courtney Smith, Paul Larsen, and Terry Walter.
A Thank You from AFTD’s Events Department
This past fiscal year (July 1, 2024 – June 30, 2025) has been remarkable to watch unfold. Thanks to the dedication of our fundraising volunteers and the generosity of their supporters, $770,000 has been raised to further AFTD’s mission. Each dollar donated reflects the passion and purpose of a community that refuses to let FTD go unnoticed.
As more people join the AFTD community, we’ve seen a surge in both the number of and the creativity in our fundraisers. From musical showdowns to movie set replicas, fundraising volunteers like you are finding new ways to raise awareness of this disease and critical funds for our mission—and AFTD’s Events Department is committed to evolving with you, providing the tools and support needed to bring each event to life.
Looking ahead, you can count on new opportunities and improved resources so we can continue to improve together. Your dedication fuels our progress and AFTD’s mission. To our fundraising volunteers past, present, and future: Thank you so much for giving your time, energy, and heart to this work. Together we are making a difference. Together, we are paving the path forward to a future free of FTD.
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)